Sage advice: psychiatric drug development is tough | Evaluate
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics Reports Results of SAGE-217 in P-III MOUNTAIN Study for Major Depressive Disorders
Discovering, developing and delivering life-changing therapies to treat rare central nervous system disorders.
An Update On Sage Therapeutics (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage advice: psychiatric drug development is tough | Evaluate
Shionogi, Sage to Partner on Developing Depression Drug in Three Asian Markets
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
BioWorld
Biogen and Sage Therapeutics in Global Collaboration – ISPE Boston
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Deals In Depth: November 2020 :: Generics Bulletin
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20161231.htm
